Assessing the PeDAL platform as a means to identify drug-and-tumor pairings
You’re among the first to have an advanced look at our Proof of Concept Study for the PeDAL platform from Predictive Oncology that features a unique combination of AI technology, drug response data and a biobank of over 150,000 tumor samples for 137 tumor types. We knew this proprietary trio of assets held strong promise—but until now, there wasn’t proof of the collective advantage.
This full report has not yet been released publicly. To access the advanced look, please enter your information below.